SCHEDULE 13G/A: Perceptive Advisors Discloses 5.1% Stake in Verrica Pharmaceuticals

Perceptive Advisors and its affiliated entities have reported a 5.1% beneficial ownership stake in Verrica Pharmaceuticals Inc., totaling 4,731,150 shares, as of December 31, 2024.

Summary

• Perceptive Advisors LLC, Joseph Edelman, and Perceptive Life Sciences Master Fund, Ltd. (collectively, the "Reporting Persons") have filed an Amendment No. 9 to Schedule 13G, disclosing their beneficial ownership in Verrica Pharmaceuticals Inc.
• As of December 31, 2024, the Reporting Persons collectively beneficially own 4,731,150 shares of Verrica Pharmaceuticals Inc. Common Stock.
• This ownership represents 5.1% of the Issuer's outstanding Common Stock.
• The ownership percentage is calculated based on 90,564,840 outstanding shares of Common Stock, as reported by Verrica Pharmaceuticals Inc. in its prospectus supplement filed on November 21, 2024.
• The total beneficial ownership includes 3,249,669 shares of Common Stock directly held by Perceptive Life Sciences Master Fund, Ltd., and 1,481,481 Pre-Funded Warrants immediately exercisable for shares of Common Stock.
• The Pre-Funded Warrants have an exercise price of $0.0001 per share and are subject to a Beneficial Ownership Limitation of 9.99%, which currently permits the exercise of all held warrants.
• Perceptive Advisors LLC serves as the investment manager to the Master Fund, and Joseph Edelman is the managing member of Perceptive Advisors.

Sentiment

Score: 5

Explanation: The document is a factual report of beneficial ownership and does not contain subjective language or performance metrics to indicate a strong positive or negative sentiment. It is neutral in tone.

Positives

• The ability of the Reporting Persons to exercise all of their 1,481,481 Pre-Funded Warrants, as the Beneficial Ownership Limitation of 9.99% is not currently met.

Future Outlook

The document is a historical report of beneficial ownership and does not provide forward-looking statements regarding Verrica Pharmaceuticals Inc.'s business operations or financial performance. It only notes that the current beneficial ownership limitation permits the exercise of all Pre-Funded Warrants held by the Reporting Persons.

Industry Context

NA

Stakeholder Impact

• Shareholders: Disclosure of a significant institutional investor's stake provides transparency regarding the company's ownership structure and can be interpreted as a vote of confidence from a major investment firm specializing in life sciences.

Key Dates

Keywords

Verrica Pharmaceuticals, Perceptive Advisors, Joseph Edelman, Perceptive Life Sciences Master Fund, Beneficial Ownership, Schedule 13G, Common Stock, Pre-Funded Warrants, Pharmaceutical, Biotech